- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01257594
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Pilot Study of EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New Jersey
-
Basking Ridge, New Jersey, United States, 07920
- Memorial Sloan-Kettering at Basking Ridge
-
-
New York
-
Commack, New York, United States, 11725
- Memorial Sloan-Kettering Cancer Center at Commack
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed intracranial malignant glioma of the following types: Glioblastoma (GBM), Gliosarcoma (GS), Anaplastic astrocytoma (AA), Anaplastic oligodendroglioma (AO), Anaplastic oligoastrocytoma (AOA, also called anaplastic mixed gliomas or AMG), High grade glioma not otherwise specified (NOS).
- EGFRvIII mutation detected on pretreatment tissue from at least 1 prior surgery.
- At least 15 unstained slides or at least 1 tissue blocks must be collected from at least one prior surgery.
- Recovered from toxic effects of prior therapies.
- Able to undergo contrast enhanced MRI scans (or CT scans for patients unable to tolerate MRI).
- Shown unequivocal evidence for contrast enhancing tumor progression by MRI (or CT for patients who cannot tolerate MRI) in comparison to a prior scan.
- Age > or = 18 years.
- Karnofsky Performance Status > or = 60%.
- Life expectancy of > 8 weeks.
- Normal organ and marrow function, adequate liver function and adequate renal function before starting therapy.
- Women of child-bearing potential and men must agree to use adequate contraception.
- Women of childbearing potential must have a negative pregnancy test documented within 7 days prior to treatment.
- Women must agree not to breast feed.
- Ability to understand and the willingness to sign a written informed consent document.
- Ability to swallow the tablets.
Cohort A (medical) specific inclusion criteria:
- Fulfill all of the general inclusion criteria.
- MRI/CT must demonstrate measurable enhancing tumor of at least 1cm2 in cross-sectional area to allow assessment of radiographic response, unless: measurable disease is not present because the patient underwent gross total resection as the most recent anti-tumor therapy.
- At least 3 months have elapsed between any prior brain radiotherapy and initiation of study therapy.
- MRI/CT must demonstrate measureable enhancing tumor at least 1cm by 1cm squared in cross-sectional area to allow assessment of radiographic response.
- Stable or decreasing dose of corticosteroids for a minimum of 5 days before the baseline MRI/CT.
- The baseline MRI/CT must be performed on the 14th day or less prior to initiation of study treatment.
Cohort B (surgical) specific inclusion criteria:
- Fulfill all of the general inclusion criteria.
- An MRI/CT scan showing progression is required.
Exclusion Criteria:
- Received prior treatment with convection enhanced delivery, other catheter based intratumoral treatment, or carmustine (BCNU)/Gliadel wafers.
- Prior therapy that included stereotactic radiosurgery during therapy for newly diagnosed or recurrent disease, or re-irradiation of any type, must have confirmation of true progressive disease rather than radiation necrosis based upon surgical documentation of recurrent/progressive disease.
- Prior treatment with an EGFR inhibitor.
- Received prior treatment with direct Vascular endothelial growth factor (VEGF)/Vascular Endothelial Growth Factor Receptors (VEGFR) inhibitors.
- Smoking or plan to smoke tobacco or marijuana during study therapy.
- Receiving any other investigational agents concurrently with study treatment.
- Taking Enzyme Inducing Anti-Epileptic Drug (EIAED). If previously on an EIAED, the patient must be off of it for at least two weeks prior to study treatment.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib.
- Uncontrolled intercurrent illness that would limit compliance with study requirements.
- Have HIV and are receiving combination antiretroviral therapy.
- Other active concurrent malignancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: No cytoreductive surgery planned
Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial.
They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
|
For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days.
For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days).
One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital "on call" to the operating room.
Other Names:
|
Experimental: Cytoreductive surgery planned
Patients scheduled for "salvage" resection as part of their routine care will be considered for this cohort.
They will receive 1 pre-operative dose of 2000 mg erlotinib.
Resection will occur ≤ 3 hours after the pre-operative dose.
After recovery from surgery, patients will resume pulsatile erlotinib dosing.
|
For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days.
For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days).
One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital "on call" to the operating room.
Other Names:
Standard procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate (either radiographic response or at least 6 months of progression-free survival)
Time Frame: Up to 3 years
|
All patients will have their tumor measurements recorded at baseline and at the time of each MRI/CT scan. Clinical efficacy of pulsatile dosing with the EGFR Tyrosine Kinase Inhibitor erlotinib in patient with EGFR vIII mutant, recurrent malignant gliomas will be explored by determination of radiographic response and 6 month progression-free survival (6mPFS rate). |
Up to 3 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andrew Lassman, MD, Columbia University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioma
- Brain Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
Other Study ID Numbers
- AAAJ7500
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...UnknownCancer | Metastatic Cancer | Metastatic Brain CancerChina
-
University of FloridaCompletedBrain Neoplasms | Brain Cancer | Brain Tumors | Seizure | Cancer of the Brain | Cancer of BrainUnited States
-
Eisai Inc.CompletedMetastatic Brain CancerUnited States
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Head and Neck Cancer | Gynecologic Cancer | Brain CancerCanada
-
InSightecActive, not recruitingGlioma | Metastatic Brain CancerCanada
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Virginia Commonwealth UniversityUnited States Department of DefenseActive, not recruitingBrain Metastases, Adult | Cancer Metastatic to BrainUnited States
-
Stanford UniversityTerminatedCancer | Brain CancerUnited States
Clinical Trials on erlotinib
-
National Cancer Institute (NCI)University of Chicago; City of Hope Medical Center; University of Southern California and other collaboratorsCompleted
-
PfizerCompletedCarcinoma, Non-Small-Cell LungUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
Kyowa Kirin Co., Ltd.TerminatedNon-small-cell Lung CancerJapan
-
Merck Sharp & Dohme LLCCompleted
-
University of ChicagoNational Cancer Institute (NCI)CompletedMalignant Peritoneal MesotheliomaUnited States
-
New Mexico Cancer Care AllianceCompletedAdvanced Solid Tumor MalignanciesUnited States
-
Duke UniversityBristol-Myers Squibb; Genentech, Inc.Completed